Prana Meets Primary Endpoint in Phase 2 REACH2HD Clinical Study of PBT2 for Treating Huntington Disease

[PR Newswire] – Secondary endpoint: Statistically significant improvement in a measure of executive function(cognition) in research participants administered 250mg PBT2 daily (p=0.042). PBT2 250mg was also associated with a favourable signal in functiona more

View todays social media effects on PRAN

View the latest stocks trending across Twitter. Click to view dashboard

See who Prana is hiring next, click here to view